R

ise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? After all, consider the alternatives. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of cinnamon and vanilla — and get started. Meanwhile, do keep us in mind if you hear anything interesting. We love secrets. Have a smashing day.

Takeda Pharmaceuticals (TKPYY), which is Japan’s largest drug maker, is considering a bid for Shire (SHPG) to help expand in rare diseases such as hemophilia, as well as hyperactivity drugs, and to gain greater entree to the U.S. market, Reuters writes. For now, Takeda says its interest is “at a preliminary and exploratory stage” and no approach has been made to the Shire board, but the company has until April 25 to decide whether to make a bid. Shire has been under pressure due to greater competition from generic drugs and a debt pile that stems from its $32 billion acquisition of Baxalta in 2016.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.